Gene Therapy Business

Detail Information

With the aim of commercialization, Takara Bio advances the clinical development of gene therapies that target diseases such as cancer.

Gene Therapy

Through gselection and concentration,h we aim to quickly get products to market by selecting development projects where Takara Bio will on its own complete all steps up to applying for approval. Takara Bio also conducts joint development with partners as joint projects.

Cell culture


Oncolytic Virus

HF10

HF10 is an attenuated strain of the herpes simplex virus 1 (HSV-1) that exhibits antitumor activity when inserted into a cancerous region. The administration of HF10 also strengthens immunity to cancer cells, giving it promise as a means to prevent tumors from forming, even in tumor regions where HF10 was not administered. This type of virus is called an oncolytic virus. Oncolytic viruses selectively replicate within tumorous tissue and break it down without doing excessive damage to normal tissue. As an independent development project, we are currently conducting clinical trials targeting malignant melanoma at the National Cancer Center Hospital and other facilities. Takara Bio aims for commercialization by fiscal 2019. And, in the U.S., we are working with partners to conduct clinical trials for malignant melanoma at such organizations as the Huntsman Cancer Institute. In Japan, we have begun clinical trials targeting pancreatic cancer.



Engineered T Cell Therapy

1. siTCR Gene Therapy

TCR gene therapies involve transducing autologous lymphocytes with TCR genes capable of recognizing cancer antigens, putting the lymphocytes back into the patient, and allowing these lymphocytes to identify and attack cancer cells, thereby eliminating cancer cells. We are developing siTCR gene therapy that involves the use of our proprietary siTCR vector technique The siTCR vector technique is thought to reduce the risk of side effects and improve effectiveness. As an independent development project, we have begun clinical trials for NY-ESO-1 siTCR gene therapy targeting synovial sarcoma and aim to achieve commercialization in fiscal 2021. Takara Bio is also currently conducting clinical development of siTCR gene therapies as a joint project with Mie University.

2. CAR Gene Therapy

Chimeric Antigen Receptors (CARs) are receptors that are made by artificially combining parts derived from antibodies that specifically recognize certain cancer antigens with parts with cytotoxic functions derived from T-cell receptors. CAR gene therapies involve putting autologous lymphocytes transduced with CAR genes back into the patient, allowing these lymphocytes to identify and attack cancer cells, thereby eliminating them. As an independent development project, Takara Bio has begun clinical trials for CD19 CAR gene therapy targeting adult acute lymphocytic leukemia and aims to commercialize by 2021. We are also working with Jichi Medical University to further conduct clinical research targeting non-Hodgkin lymphoma, a type of malignant lymphoma.

Business Outline

return to top